A carregar...
Nivolumab and Ipilimumab in the Treatment of Metastatic Uveal Melanoma: A Single-Center Experience
BACKGROUND: Metastatic uveal melanoma (MUM) is associated with a poor prognosis, with a median overall survival (OS) of 4–15 months. Despite new insights into the genetic and molecular background of MUM, satisfactory systemic treatment approaches are currently lacking. The study results of innovativ...
Na minha lista:
| Publicado no: | Case Rep Oncol Med |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hindawi
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6501230/ https://ncbi.nlm.nih.gov/pubmed/31179139 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2019/3560640 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|